BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 29743404)

  • 1. [Epigenetic aberrations in adult T-cell leukemia/lymphoma and development of a novel EZH1/2 inhibitor].
    Yamagishi M
    Rinsho Ketsueki; 2018; 59(4):432-438. PubMed ID: 29743404
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting Excessive EZH1 and EZH2 Activities for Abnormal Histone Methylation and Transcription Network in Malignant Lymphomas.
    Yamagishi M; Hori M; Fujikawa D; Ohsugi T; Honma D; Adachi N; Katano H; Hishima T; Kobayashi S; Nakano K; Nakashima M; Iwanaga M; Utsunomiya A; Tanaka Y; Okada S; Tsukasaki K; Tobinai K; Araki K; Watanabe T; Uchimaru K
    Cell Rep; 2019 Nov; 29(8):2321-2337.e7. PubMed ID: 31747604
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Unlocking adult T-cell leukemia/lymphoma's epigenetic secrets: delving into the mechanism and impact of EZH1/2 inhibition.
    Tavakoli Shirazi P; Bywater MJ
    Immunol Cell Biol; 2024; 102(5):298-301. PubMed ID: 38606590
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polycomb Repressive Complex 2 Proteins EZH1 and EZH2 Regulate Timing of Postnatal Hepatocyte Maturation and Fibrosis by Repressing Genes With Euchromatic Promoters in Mice.
    Grindheim JM; Nicetto D; Donahue G; Zaret KS
    Gastroenterology; 2019 May; 156(6):1834-1848. PubMed ID: 30689973
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polycomb-dependent epigenetic landscape in adult T-cell leukemia.
    Fujikawa D; Nakagawa S; Hori M; Kurokawa N; Soejima A; Nakano K; Yamochi T; Nakashima M; Kobayashi S; Tanaka Y; Iwanaga M; Utsunomiya A; Uchimaru K; Yamagishi M; Watanabe T
    Blood; 2016 Apr; 127(14):1790-802. PubMed ID: 26773042
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ezh1 and Ezh2 differentially regulate PSD-95 gene transcription in developing hippocampal neurons.
    Henriquez B; Bustos FJ; Aguilar R; Becerra A; Simon F; Montecino M; van Zundert B
    Mol Cell Neurosci; 2013 Nov; 57():130-43. PubMed ID: 23932971
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Valemetostat: First approval as a dual inhibitor of EZH1/2 to treat adult T-cell leukemia/lymphoma.
    Dou F; Tian Z; Yang X; Li J; Wang R; Gao J
    Drug Discov Ther; 2022 Dec; 16(6):297-299. PubMed ID: 36310058
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanisms of action and resistance in histone methylation-targeted therapy.
    Yamagishi M; Kuze Y; Kobayashi S; Nakashima M; Morishima S; Kawamata T; Makiyama J; Suzuki K; Seki M; Abe K; Imamura K; Watanabe E; Tsuchiya K; Yasumatsu I; Takayama G; Hizukuri Y; Ito K; Taira Y; Nannya Y; Tojo A; Watanabe T; Tsutsumi S; Suzuki Y; Uchimaru K
    Nature; 2024 Mar; 627(8002):221-228. PubMed ID: 38383791
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Flow-dependent epigenetic regulation of IGFBP5 expression by H3K27me3 contributes to endothelial anti-inflammatory effects.
    Xu S; Xu Y; Yin M; Zhang S; Liu P; Koroleva M; Si S; Little PJ; Pelisek J; Jin ZG
    Theranostics; 2018; 8(11):3007-3021. PubMed ID: 29896299
    [No Abstract]   [Full Text] [Related]  

  • 10. [EZH inhibitors in lymphoma therapy].
    Ishitsuka K
    Rinsho Ketsueki; 2023; 64(7):665-669. PubMed ID: 37544728
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel orally bioavailable EZH1/2 dual inhibitors with greater antitumor efficacy than an EZH2 selective inhibitor.
    Honma D; Kanno O; Watanabe J; Kinoshita J; Hirasawa M; Nosaka E; Shiroishi M; Takizawa T; Yasumatsu I; Horiuchi T; Nakao A; Suzuki K; Yamasaki T; Nakajima K; Hayakawa M; Yamazaki T; Yadav AS; Adachi N
    Cancer Sci; 2017 Oct; 108(10):2069-2078. PubMed ID: 28741798
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EZH1 mediates methylation on histone H3 lysine 27 and complements EZH2 in maintaining stem cell identity and executing pluripotency.
    Shen X; Liu Y; Hsu YJ; Fujiwara Y; Kim J; Mao X; Yuan GC; Orkin SH
    Mol Cell; 2008 Nov; 32(4):491-502. PubMed ID: 19026780
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EZH1/2 inhibition augments the anti-tumor effects of sorafenib in hepatocellular carcinoma.
    Kusakabe Y; Chiba T; Oshima M; Koide S; Rizq O; Aoyama K; Ao J; Kaneko T; Kanzaki H; Kanayama K; Maeda T; Saito T; Nakagawa R; Kobayashi K; Kiyono S; Nakamura M; Ogasawara S; Suzuki E; Nakamoto S; Yasui S; Mikata R; Muroyama R; Kanda T; Maruyama H; Kato J; Mimura N; Ma A; Jin J; Zen Y; Otsuka M; Kaneda A; Iwama A; Kato N
    Sci Rep; 2021 Nov; 11(1):21396. PubMed ID: 34725436
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An orally bioavailable chemical probe of the Lysine Methyltransferases EZH2 and EZH1.
    Konze KD; Ma A; Li F; Barsyte-Lovejoy D; Parton T; Macnevin CJ; Liu F; Gao C; Huang XP; Kuznetsova E; Rougie M; Jiang A; Pattenden SG; Norris JL; James LI; Roth BL; Brown PJ; Frye SV; Arrowsmith CH; Hahn KM; Wang GG; Vedadi M; Jin J
    ACS Chem Biol; 2013; 8(6):1324-34. PubMed ID: 23614352
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Maternal Ezh1/2 deficiency in oocyte delays H3K27me2/3 restoration and impairs epiblast development responsible for embryonic sub-lethality in mouse.
    Zhao Y; Bai D; Wu Y; Zhang D; Liu M; Tian Y; Lu J; Wang H; Gao S; Lu Z
    Development; 2022 Aug; 149(15):. PubMed ID: 35796552
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sex-biased genetic programs in liver metabolism and liver fibrosis are controlled by EZH1 and EZH2.
    Lau-Corona D; Bae WK; Hennighausen L; Waxman DJ
    PLoS Genet; 2020 May; 16(5):e1008796. PubMed ID: 32428001
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EZH1 in germ cells safeguards the function of PRC2 during spermatogenesis.
    Mu W; Starmer J; Shibata Y; Yee D; Magnuson T
    Dev Biol; 2017 Apr; 424(2):198-207. PubMed ID: 28254491
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of EZH1 and EZH2 in development and cancer.
    Lee SH; Li Y; Kim H; Eum S; Park K; Lee CH
    BMB Rep; 2022 Dec; 55(12):595-601. PubMed ID: 36476271
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulation of Retinal Development via the Epigenetic Modification of Histone H3.
    Watanabe S; Murakami A
    Adv Exp Med Biol; 2016; 854():635-41. PubMed ID: 26427469
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structure-Activity Relationship Studies for Enhancer of Zeste Homologue 2 (EZH2) and Enhancer of Zeste Homologue 1 (EZH1) Inhibitors.
    Yang X; Li F; Konze KD; Meslamani J; Ma A; Brown PJ; Zhou MM; Arrowsmith CH; Kaniskan HÜ; Vedadi M; Jin J
    J Med Chem; 2016 Aug; 59(16):7617-33. PubMed ID: 27468126
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.